Advanced Urothelial Carcinoma
Advertisement
The phase 3 KEYNOTE-A39/EV-302 study has met its dual primary end points of OS and PFS in advanced or metastatic UC.
Dr. de Kouchkovsky highlights survival and response rates after ICIs and EV for patients with squamous histology.
Dr. de Kouchkovsky explains studying the impact of squamous histology on clinical outcomes in mUC after ICIs or EV.
The positive results were consistent with findings from the primary analysis, such as PFS and overall response benefit.
Multiple genitourinary oncology therapies are in the spotlight this week, with new US FDA indications on the horizon.
Somatic alterations in DDR genes are common in patients with advanced urothelial cancer.
Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.
Drs. Shilpa Gupta and Vadim Koshkin discuss the EV-103 trial and data, including long-term results for cohort A.
Enfortumab vedotin and pembrolizumab have shown a survival benefit as individual treatments in locally advanced and mUC.
Tanya Jindal expands upon the UNITE study findings relative to biomarkers of response for SG and EV for advanced UC.
Nivolumab and cisplatin-based chemotherapy administered before nivolumab alone demonstrates significant OS and PFS benefit.
Drs. Loriot, Koshkin summarize erdafitinib versus chemotherapy in patients with advanced UC with select FGFR alterations.
Drs. Powles and Koshkin break down the Q-TWiST analysis conducted on the JAVELIN Bladder 100 study for advanced UC.
Drs. Lerner and Koshkin explain the implications of the latest data from the SWOG S1011 study for mUC.
Drs. Friedlander and Koshkin highlight the 18-month data from the EV-103 study on EV/pembro first-line mUC treatment.
Drs. Siefker-Radtke and Koshkin detail the NORSE study design, results, and implications for treating patients with mUC.
A post hoc analysis of the IMvigor130 trial examined OS outcomes during first-line induction for patients with mUC.
KEYNOTE-361: Complete Response Outcomes With First-line Pembrolizumab or Platinum-Based Chemotherapy
A post hoc exploratory analysis of the KEYNOTE-361 study was presented at the 2023 ASCO annual meeting.
Drs. Koshkin and Basu comment on the best available treatment approach for patients with ctDNA-positive MIBC after surgery.
Drs. Koshkin, Basu break down treatment considerations based on ctDNA status after radical cystectomy, among other factors.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.